ORG – Page 2 – Talk Bio

BioMarin Plans to Divest Hemophilia Gene Therapy Roctavian Amid Strategic Refocus

2 days ago talkbio0Tagged BioMarin, Divestment, gene therapy, Hemophilia A, out-licensing, portfolio strategy, Roctavian

BioMarin; Roctavian; hemophilia A; gene therapy; divestment; out-licensing; portfolio strategy; third quarter 2025; revenue challenge

Jazz Pharmaceuticals Appoints Dr. Ted Love to Board of Directors

2 days ago talkbio0Tagged Audit Committee, Board appointment, board of directors, Corporate governance, Jazz, Kenneth W. O’Keefe, Retirement, Science, Ted Love

Jazz Pharmaceuticals; Ted Love; Board appointment; Board of Directors; Corporate governance; Audit Committee; Science and Medicine Committee; Kenneth W. O’Keefe retirement

Cigna Announces End to Drug Rebates for Many Health Plans Beginning in 2027

2 days ago talkbio0Tagged brand-name prescriptions, Cigna, drug price, drug rebates, Evernorth, Express Scripts, manager, Pharmaceutical Services, pharmacy reimbursement, Trump administration, upfront discounts

Cigna; drug rebates; pharmacy benefit manager; Evernorth; Express Scripts; upfront discounts; brand-name prescriptions; pharmacy reimbursement; Trump administration; drug pricing

Intellia Pauses Two CRISPR Trials After Severe Liver Toxicity Hospitalizes Patient

3 days ago talkbio0Tagged Clustered Regularly Interspaced Short Palindromic Repeats, Gene Modification, Hospitalization, Intellia, Liver, Pauses, Phase 3 Clinical Trials, Safety, Senile cardiac amyloidosis, Toxicity aspects

Intellia Therapeutics; CRISPR; transthyretin amyloidosis; Phase III trials; gene editing; liver toxicity; patient hospitalization; safety pause

BridgeBio Shifts Filing Plans After Phase 3 Success in Rare Disease Drug BBP-418

3 days ago talkbio0Tagged Acoramidis, Approved, BBP-418, Biological Markers, BridgeBio, commercial, disease drug, File (record), Infrequent, Limb-girdle muscular dystrophy type 2A, NDA, New Drug Application, Phase 3 success, Ribitol, United States Food and Drug Administration

BridgeBio; BBP-418; Phase 3 success; limb-girdle muscular dystrophy type 2I/R9; FDA filing; rare disease drug; NDA (New Drug Application); ribitol; full approval; biomarker; acoramidis; commercial strategy

OpenAI Collaborates with Thermo Fisher and Lundbeck to Enhance Pharma Research

3 days ago talkbio0Tagged DNA Integration, Lundbeck, OpenAI, Pharma, Thermo Fisher

OpenAI; Thermo Fisher; Lundbeck; Pharma; AI Integration

Clearmind Medicine Appoints Mary-Elizabeth Gifford as Chief of Global Impact

3 days ago talkbio0Tagged Clearmind Medicine, Clinical Trials, governmental engagement, Mary-Elizabeth, mental health, partnerships, psychedelic medicine, regulatory advocacy, U.S.

Clearmind Medicine; Mary-Elizabeth Gifford; Chief of Global Impact; psychedelic medicine; US partnerships; governmental engagement; regulatory advocacy; biotech company; clinical trials; mental health

GSK Secures Exclusive Rights to Syndivia’s Preclinical Prostate Cancer ADC in $357 Million Deal

3 days ago talkbio0Tagged asset, GeminiMab technology, Licensing, Malignant neoplasm of prostate, Metastatic castration-resistant prostate cancer, milestone payments, Oncology Pipeline, Preclinical, SmithKline Beecham, Syndivia, therapeutic autologous dendritic cells

GSK; Syndivia; ADC; prostate cancer; metastatic castration-resistant prostate cancer; exclusive licensing; oncology pipeline; GeminiMab technology; milestone payments; preclinical asset

Edison Oncology Presents Two Posters at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

3 days ago talkbio0Tagged AACR-NCI-EORTC, ARID1A mutation, Clinical Trials, Edison Oncology, Molecular Targets, Orotecan, ovarian neoplasm, OXPHOS pathway, Phase 1 - 2a, VAL-413

Edison Oncology; 2025 AACR-NCI-EORTC; Molecular Targets; Cancer Therapeutics; VAL-413; Orotecan; EO3001; ARID1A mutation; ovarian cancer; Phase 1-2a clinical trial; OXPHOS pathway

From JP Morgan to the Next Wave: What’s Driving Biotech in 2026

3 days ago talkbio0Tagged 2026, Artificial Intelligence, Drug Discovery, Hematology (discipline), Investments, J.P. Morgan Healthcare Conference, M&A activity, Neoplasms, Neuropsychology, regulatory science, trends qualifier

J.P. Morgan Healthcare Conference; biotech trends 2026; M&A activity; oncology; neuropsychology; hematology; artificial intelligence; drug discovery; investment; regulatory science